News
News
Stories, statements and updates from Rett Syndrome Europe and our member associations across Europe.
-
Rett Forum 2026 brings Europe’s Rett syndrome community together in Madrid
Clinicians, researchers, patient experts and association leaders meet on 6–8 November to agree shared priorities for care and research
-
One week to go: Rett Forum brings Europe together to advance Rett care
On 6–8 November 2026, Rett Forum will bring clinicians, researchers, patient organisations and industry partners together in Madrid to lay the foundations for more consistent, coordinated Rett syndrome care across Europe.
-
A hopeful milestone for the Rett community in Europe
Rett Syndrome Europe welcomes the positive CHMP opinion for Daybu (trofinetide), a meaningful milestone for families affected by Rett syndrome across Europe.
-
Taysha Reports Progress on TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies has shared positive longer-term interim data from its investigational gene therapy TSHA-102, with dosing now complete in the pivotal study and regulatory discussions planned for 2027.
-
Hopeful Progress: Gene Therapy Trial for Rett Syndrome Completes Enrollment
Neurogene has announced the successful completion of enrollment in the EMBOLDEN trial of NGN-401, an investigational gene therapy for Rett syndrome. The trial exceeded its target, treating 25 participants due to high demand from the community.
-
Rett Syndrome Europe at ECRD 2026: Advancing Visibility, Data, and Care
Rett Syndrome Europe took part in ECRD 2026 with two posters — the rettX patient registry and a study on unmet needs and fragmented care across Europe.
-
Consistent Unmet Needs and Fragmented Care in Rett Syndrome Across Europe
A multi-country caregiver study presented by Rett Syndrome Europe at ECRD 2026 reveals consistent unmet needs and fragmented care across Europe.
-
rettX: Building a Patient-Led Rett Syndrome Registry for Europe
rettX is the pan-European, patient-led Rett syndrome registry led by Rett Syndrome Europe, presented at ECRD 2026. Learn what it is and how families can take part.
-
Statement from Rett Syndrome Europe
Regarding the CHMP Opinion on Trofinetide The European Medicines Agency (EMA) has announced that its Committee for Medicinal Products for Human Use (CHMP) has recommended not granting marketing authorisation for Trofinetide for the treatment of Rett syndrome in Europe. According to EMA, the CHMP concluded that the treatment effects observed after 12 weeks were not sufficient…
-
International Rett Syndrome Conference – Istanbul, Turkey 11th – 12th October 2025
Registration is now open for the International Rett Syndrome Conference in Istanbul! A unique gathering for doctors, scientists, families, and therapists! Be a part of this important event and stay up to date with the latest scientific developments in the Rett syndrome field! Register here now! The International Rett Syndrome Conference 2025 is now open…
Stay connected
Follow Rett Syndrome Europe
For the latest stories, events and research updates, follow us on social media.